Skip to main content

Table 4 The univariate and multivariate analyses for relapse

From: Dual time point 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer

Parameter (Favorable vs. Unfavorable)

Univariate

Multivariate

 

Including

SUVmax1

Including

ΔSUVmax%

Including

SUVmax1/ΔSUVmax%

Hazard ratio

P-value

Hazard ratio

P-value

Hazard ratio

P-value

Hazard ratio

P-value

(95% CI)

(95% CI)

(95% CI)

(95% CI)

Pathological T factor

4.9

< 0.0001

2.35

0.0229

2.5

0.0155

2.21

0.0392

 (pT2, pT3 vs. pTis, pT1)

(2.48–10.3)

(1.12–5.24)

(1.18–5.62)

(1.03–5.02)

Nuclear grade

4.79

< 0.0001

2.46

0.0303

2.79

0.0125

2.57

0.0222

 (3 vs. 1, 2)

(2.34–10.7)

(1.08–6.10)

(1.23–6.97)

(1.13–6.39)

Lymphovascular invasion

7.32

< 0.0001

4.83

0.0007

4.36

0.0015

4.92

0.0006

 (Positive vs. Negative)

(3.28–19.5)

(1.87–14.6)

(1.70–13.0)

(1.90–14.9)

Estrogen receptor

1.46

0.339

      

 (Negative vs. Positive)

(0.65–2.97)

      

Progesterone receptor

1.34

0.404

      

 (Negative vs. Positive)

(0.65–2.63)

      

HER2

1.08

0.879

      

 (Positive vs. Negative)

(0.32–2.73)

      

Ki-67 labeling index

3.38

0.0012

1.62

0.247

1.83

0.139

1.68

0.212

 (≥ 14.0 vs. < 14.0)

(1.58–8.06)

(0.72–4.04)

(0.83–4.50)

(0.75–4.18)

Pathological N factor

4.47

< 0.0001

1.52

0.261

1.52

0.268

1.51

0.276

 (pN1, pN2, pN3 vs. pN0)

(2.32–8.92)

(0.73–3.32)

(0.73–3.35)

(0.72–3.30)

SUVmax1

3.61

0.0003

2.54

0.0267

    

 (≥ 3.4 vs. <  3.4)

(1.77–8.13)

(1.10–6.46)

    

ΔSUVmax%

2.46

0.0122

  

1.74

0.152

  

 (≥ 12.5 vs. <  12.5)

(1.20–5.53)

  

(0.82–4.07)

  

SUVmax1/ΔSUVmax%

3.24

0.0007

    

2.33

0.0283

 (Group A vs. Group B/C)

(1.62–6.72)

    

(1.09–5.31)

  1. CI, confidence interval
  2. HER2, human epidermal growth factor receptor 2
  3. SUV, standardized uptake value
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us